GRF Stock Analysis: Grifols S.A. | MC
Drug Manufacturers - General | MC, Spain | Market Cap: 6.770m EUR | 12M Return: -17.7% | ES0171996087 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.2M
EPS Trend: 96.7%
Qual. Beats: 0
Rev. Trend: 92.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Grifols, S.A. is a Spanish healthcare company founded in 1909 and headquartered in Barcelona that researches, develops, produces, and markets plasma-derived medicines. The company operates in the United States, Canada, Spain, Europe, and other international markets through four business segments: Biopharma, Diagnostic, Bio Supplies, and Others.
The Biopharma segment forms the core of the business, offering hemoderivatives from human plasma used in immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology. The Diagnostic segment markets testing equipment, reagents, and transfusion medicine services, while Bio Supplies provides biological products such as albumin, immunoglobulins, and intermediate plasma products to third-party pharma and biotech firms, as well as whole blood, blood components, and clinical samples to life-science research and in-vitro diagnostic companies.
In addition, Grifols provides a range of hospital healthcare solutions, including intravenous solutions, clinical nutrition, and medical devices used in interventional neuroradiology, hemodynamics, urology, anesthesiology, and cardiovascular surgery. The company also engages in contract manufacturing, packaging, distribution, engineering, reinsurance, and various administrative and consulting services.
The plasma-derived therapeutics industry is characterized by high barriers to entry due to stringent regulatory requirements, long manufacturing lead times, and the need for vertically integrated plasma collection networks to secure raw material supply.
- Immunoglobulin demand drives Biopharma segment growth
- Plasma collection costs pressure gross margins
- Diagnostic division revenue grows on transfusion medicine demand
- US dollar weakness pressures euro reported revenue
| Net Income: 452.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.29 > 1.0 |
| NWC/Revenue: 41.35% < 20% (prev 43.73%; Δ -2.38% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.09b > Net Income 452.1m |
| Net Debt (9.03b) to EBITDA (1.75b): 5.17 < 3 |
| Current Ratio: 2.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.6m) vs 12m ago -1.17% < -2% |
| Gross Margin: 37.23% > 18% (prev 40.65%; Δ -3.42% > 0.5%) |
| Asset Turnover: 37.24% > 50% (prev 37.67%; Δ -0.43% > 0%) |
| Interest Coverage Ratio: 2.45 > 6 (EBIT TTM 1.31b / Interest Expense TTM 534.3m) |
| A: 0.15 (Total Current Assets 5.30b - Total Current Liabilities 2.24b) / Total Assets 20.1b |
| B: 0.01 (Retained Earnings 227.0m / Total Assets 20.1b) |
| C: 0.07 (EBIT TTM 1.31b / Avg Total Assets 19.9b) |
| D: 0.46 (Book Value of Equity 5.55b / Total Liabilities 12.1b) |
| Altman-Z'' = 1.96 = BBB |
| DSRI: 0.95 (Receivables 1.19b/1.25b, Revenue 7.42b/7.45b) |
| GMI: 1.09 (GM 40.65% / 37.23%) |
| AQI: 1.01 (AQ_t 0.53 / AQ_t-1 0.53) |
| SGI: 1.00 (Revenue 7.42b / 7.45b) |
| TATA: -0.03 (NI 452.1m - CFO 1.09b) / TA 20.1b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at EUR 9.88 with a total of 1,428,303 shares traded. Over the past week, the price has changed by +3.63%, over one month by -0.76%, over three months by +9.88% and over the past year by -17.70%.
Current recommended Stop Loss: 9.50 (which is 3.8% or 1.7 ATR below the current price).
Grifols S.A. has no consensus analysts rating.
P/E Trailing = 15.0727
P/E Forward = 8.6655
P/S = 0.9123
P/B = 1.1486
P/EG = 0.283
Revenue TTM = 7.42b EUR
EBIT TTM = 1.31b EUR
EBITDA TTM = 1.75b EUR
Long Term Debt = 7.17b EUR (from longTermDebt, last quarter)
Short Term Debt = 420.0m EUR (from shortTermDebt, last quarter)
Debt = 9.56b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.04b
Net Debt = 9.03b EUR (calculated: Debt 9.56b - CCE 529.0m)
Enterprise Value = 15.8b EUR (6.77b + Debt 9.56b - CCE 529.0m)
Interest Coverage Ratio = 2.45 (Ebit TTM 1.31b / Interest Expense TTM 534.3m)
EV/FCF = 20.61x (Enterprise Value 15.8b / FCF TTM 766.7m)
FCF Yield = 4.85% (FCF TTM 766.7m / Enterprise Value 15.8b)
FCF Margin = 10.33% (FCF TTM 766.7m / Revenue TTM 7.42b)
Net Margin = 6.09% (Net Income TTM 452.1m / Revenue TTM 7.42b)
Gross Margin = 37.23% ((Revenue TTM 7.42b - Cost of Revenue TTM 4.66b) / Revenue TTM)
Gross Margin QoQ = 37.57% (prev 36.47%)
Tobins Q-Ratio = 0.79 (Enterprise Value 15.8b / Total Assets 20.1b)
Interest Expense / Debt = 5.59% (Interest Expense 534.3m / Debt 9.56b)
Taxrate = 19.10% (127.6m / 668.3m)
NOPAT = 1.06b (EBIT 1.31b * (1 - 19.10%))
Current Ratio = 2.37 (Total Current Assets 5.30b / Total Current Liabilities 2.24b)
Debt / Equity = 1.72 (Debt 9.56b / totalStockholderEquity, last quarter 5.55b)
Debt / EBITDA = 5.17 (Net Debt 9.03b / EBITDA 1.75b)
Debt / FCF = 11.78 (Net Debt 9.03b / FCF TTM 766.7m)
Total Stockholder Equity = 5.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.27% (Net Income 452.1m / Total Assets 20.1b)
RoE = 8.43% (Net Income TTM 452.1m / Total Stockholder Equity 5.36b)
RoCE = 10.42% (EBIT 1.31b / Capital Employed (Equity 5.36b + L.T.Debt 7.17b))
RoIC = 5.90% (NOPAT 1.06b / Invested Capital 17.9b)
WACC = 5.46% (E(6.77b)/V(16.3b) * Re(6.79%) + D(9.56b)/V(16.3b) * Rd(5.59%) * (1-Tc(0.19)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -59.05 | Cagr: -1.90%
[DCF] Terminal Value 74.66% ; FCFF base≈784.5m ; Y1≈751.5m ; Y5≈724.6m
[DCF] Fair Price = 5.57 (EV 11.4b - Net Debt 9.03b = Equity 2.35b / Shares 422.4m; r=8.35% [WACC [floored]]; 5y FCF grow -5.49% → 2.50% )
EPS Correlation: 96.71 | EPS CAGR: 44.29% | SUE: -0.19 | # QB: 0
Revenue Correlation: 92.94 | Revenue CAGR: 5.90% | SUE: -0.70 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.26 | Chg30d=+4.59% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.90 | Chg30d=-0.41% | Revisions=+0% | GrowthEPS=+22.5% | GrowthRev=+1.7%
EPS next Year (2027-12-31): EPS=1.14 | Chg30d=+0.84% | Revisions=+40% | GrowthEPS=+27.2% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +38% (up=4, down=1)